Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

63 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Cabozantinib for radioiodine-refractory differentiated thyroid cancer (COSMIC-311): a randomised, double-blind, placebo-controlled, phase 3 trial.
Brose MS, Robinson B, Sherman SI, Krajewska J, Lin CC, Vaisman F, Hoff AO, Hitre E, Bowles DW, Hernando J, Faoro L, Banerjee K, Oliver JW, Keam B, Capdevila J. Brose MS, et al. Among authors: faoro l. Lancet Oncol. 2021 Aug;22(8):1126-1138. doi: 10.1016/S1470-2045(21)00332-6. Epub 2021 Jul 5. Lancet Oncol. 2021. PMID: 34237250 Clinical Trial.
A Randomized, Double-Blind Noninferiority Study to Evaluate the Efficacy of the Cabozantinib Tablet at 60 mg Per Day Compared with the Cabozantinib Capsule at 140 mg Per Day in Patients with Progressive, Metastatic Medullary Thyroid Cancer.
Capdevila J, Klochikhin A, Leboulleux S, Isaev P, Badiu C, Robinson B, Hughes BGM, Keam B, Parnis F, Elisei R, Gajate P, Gan HK, Kapiteijn E, Locati L, Mangeshkar M, Faoro L, Krajewska J, Jarzab B. Capdevila J, et al. Among authors: faoro l. Thyroid. 2022 May;32(5):515-524. doi: 10.1089/thy.2022.0027. Thyroid. 2022. PMID: 35403447 Free PMC article. Clinical Trial.
Randomized phase II study of bevacizumab in combination with chemotherapy in previously untreated extensive-stage small-cell lung cancer: results from the SALUTE trial.
Spigel DR, Townley PM, Waterhouse DM, Fang L, Adiguzel I, Huang JE, Karlin DA, Faoro L, Scappaticci FA, Socinski MA. Spigel DR, et al. Among authors: faoro l. J Clin Oncol. 2011 Jun 1;29(16):2215-22. doi: 10.1200/JCO.2010.29.3423. Epub 2011 Apr 18. J Clin Oncol. 2011. PMID: 21502556 Clinical Trial.
Activating NOTCH1 Mutations Define a Distinct Subgroup of Patients With Adenoid Cystic Carcinoma Who Have Poor Prognosis, Propensity to Bone and Liver Metastasis, and Potential Responsiveness to Notch1 Inhibitors.
Ferrarotto R, Mitani Y, Diao L, Guijarro I, Wang J, Zweidler-McKay P, Bell D, William WN Jr, Glisson BS, Wick MJ, Kapoun AM, Patnaik A, Eckhardt G, Munster P, Faoro L, Dupont J, Lee JJ, Futreal A, El-Naggar AK, Heymach JV. Ferrarotto R, et al. Among authors: faoro l. J Clin Oncol. 2017 Jan 20;35(3):352-360. doi: 10.1200/JCO.2016.67.5264. Epub 2016 Nov 21. J Clin Oncol. 2017. PMID: 27870570 Free PMC article.
Targeted and cytotoxic therapy in coordinated sequence (TACTICS): erlotinib, bevacizumab, and standard chemotherapy for non-small-cell lung cancer, a phase II trial.
Cohen EE, Subramanian J, Gao F, Szeto L, Kozloff M, Faoro L, Karrison T, Salgia R, Govindan R, Vokes EE. Cohen EE, et al. Among authors: faoro l. Clin Lung Cancer. 2012 Mar;13(2):123-8. doi: 10.1016/j.cllc.2011.10.001. Epub 2011 Nov 18. Clin Lung Cancer. 2012. PMID: 22100149 Clinical Trial.
Efficacy and safety of bevacizumab plus erlotinib for patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer: a trial of the Chicago, PMH, and California Phase II Consortia.
Nimeiri HS, Oza AM, Morgan RJ, Friberg G, Kasza K, Faoro L, Salgia R, Stadler WM, Vokes EE, Fleming GF; Chicago Phase II Consortium; PMH Phase II Consortium; California Phase II Consortium. Nimeiri HS, et al. Among authors: faoro l. Gynecol Oncol. 2008 Jul;110(1):49-55. doi: 10.1016/j.ygyno.2008.02.009. Epub 2008 Apr 18. Gynecol Oncol. 2008. PMID: 18423560 Free PMC article. Clinical Trial.
BRIDGE: an open-label phase II trial evaluating the safety of bevacizumab + carboplatin/paclitaxel as first-line treatment for patients with advanced, previously untreated, squamous non-small cell lung cancer.
Hainsworth JD, Fang L, Huang JE, Karlin D, Russell K, Faoro L, Azzoli C. Hainsworth JD, et al. Among authors: faoro l. J Thorac Oncol. 2011 Jan;6(1):109-14. doi: 10.1097/JTO.0b013e3181f94ad4. J Thorac Oncol. 2011. PMID: 21107290 Free article. Clinical Trial.
MET receptor tyrosine kinase.
Faoro L, Cervantes GM, El-Hashani E, Salgia R. Faoro L, et al. J Thorac Oncol. 2009 Nov;4(11 Suppl 3):S1064-5. doi: 10.1097/01.JTO.0000361752.86918.09. J Thorac Oncol. 2009. PMID: 19861919 Free PMC article.
63 results